The use of fluconazole and itraconazole in the treatment of Candida albicans infections: A review

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 4, 1999, Pages 429-437

  Martin, Michael V ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADRENAL INSUFFICIENCY; AGE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSPEPSIA; GYNECOMASTIA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LIVER NECROSIS; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRURITUS; RECURRENT DISEASE; REVIEW; VERTIGO; VOMITING;

ANTIFUNGAL AGENTS; CANDIDIASIS; FLUCONAZOLE; HUMANS; ITRACONAZOLE;

EID: 0032834241     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.4.429     Document Type: Review

References (93)

1. Beck-Sagúe, C. & Jarvis, W. R. (1993). Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nocosomial Infections Surveillance System. Journal of Infectious Diseases 167, 1247-51.
2. Dupont, P. F. (1995). Candida albicans, the opportunist. A cellular and molecular perspective. Journal of the American Pediatric Medical Association 85, 104-15.
3. McCullough, M. J., Ross, B. C. & Reade, P. C. (1996). Candida albicans: a review of its history, taxonomy, epidemiology, virulence attributes, and methods of strain differentiation. International Journal of Oral and Maxillofacial Surgery 25, 136-44.
4. Barchiesi, F., Morbiducci, V., Ancarani, F. & Scalise, G. (1993). Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. European Journal of Epidemiology 9, 455-6.
5. Powderly, W. G., Robinson, K. & Keath, E. J. (1993). Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. Journal of Infectious Diseases 168, 463-6.
6. Vazquez, J. A. (1999). Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy 19, 76-87.
7. Goa, K. L. & Barradell, L. B. (1995). Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50, 658-90.
8. Edwards, J. E., Jr, Bodey, G. P., Bowden, R. A., Buchner, T., de Pauw, B. E., Filler, S. G. et al. (1997). International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clinical Infectious Diseases 25, 43-59.
9. Haria, M., Bryson, H. M. & Goa, K. L. (1996). Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51, 585-620.
10. De Beule, K. (1996). Itraconazole: pharmacology, clinical experience and future development. International Journal of Antimicrobial Agents 6, 175-81.
11. Prentice, A. G., Warnock, D. W., Johnson, S. A. N., Phillips, M. J. & Oliver, D. A. (1994). Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. Journal of Antimicrobial Chemotherapy 34, 247-52.
12. Cartledge, J. D., Midgley, J. & Gazzard, B. G. (1997). Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. Journal of Clinical Pathology 50, 477-80.
13. Graybill, J. R., Vazquez, J., Darouiche, R. O., Morhart, R., Greenspan, D., Tuazon, C. et al. (1998). Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. American Journal of Medicine 104, 33-9.
14. Humphrey, M. J., Jevons, S. & Tarbit, M. H. (1985). Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug in animals and humans. Antimicrobial Agents and Chemotherapy 28, 648-53.
15. Debruyne, D. & Ryckelynck, J. P. (1993). Clinical pharmacokinetics of fluconazole. Clinical Pharmacokinetics 24, 10-27.
16. Koks, C. H., Meenhorst, P. L., Hillebrand, M. J., Bult, A. & Beijnen, J. H. (1996). Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrobial Agents and Chemotherapy 40, 1935-7.
17. Lim, S. G., Sawyerr, A. W., Hudson, M., Sercombe, J. & Pounder, R. E. (1993). Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Alimentary Pharmacology and Therapeutics 7, 317-21.
18. Zimmermann, T., Yeates, R. A., Laufen, H., Pfaff, G. & Wildfeuer, A. (1994). Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. European Journal of Clinical Pharmacology 46, 147-50.
19. Brammer, K. W. & Coates, P. E. (1994). Pharmacokinetics of fluconazole in pediatric patients. European Journal of Clinical Microbiology and Infectious Diseases 13, 325-9.
20. Saxén, H., Hoppu, K. & Pohjavuori, M. (1993). Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clinical Pharmacology and Therapeutics 54, 269-77.
21. Nahata, M. C. & Brady, M. T. (1995). Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection. European Journal of Clinical Pharmacology 48, 291-3.
22. Seay, R. E., Larson, T. A., Toscano, J. P., Bostrom, B. C., O'Leary, M. C. & Uden, D. L. (1995). Pharmacokinetics of fluconazole in immune-compromised children with leukaemia or other hematological diseases. Pharmacotherapy 15, 52-8.
23. 2 receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. British Journal of Clinical Pharmacology 27, 105P-106P.
24. De Doncker, P. & Cauwenbergh, G. (1990). Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review. British Journal of Clinical Practice. Supplement 71, 118-22.
25. Willemsen, M., De Doncker, P., Willems, J., Woestenborghs, R., Van de Velde, V., Heykants, J. et al. (1992) Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. Journal of the American Academy of Dermatology 26, 731-5.
26. Van de Velde, V. J., Van Peer, A. P., Heykants, J. J., Woestenborghs, R. J., Van Rooy, P., De Beule, K. L. et al. (1996). Effect of food on the pharmacokinetics of a new hydroxypropyl-beta cyclodextrin formulation of itraconazole. Pharmacotherapy 16, 424-8.
27. Smith, D., Van de Velde, V., Woestenborghs, R. & Gazzard, B. G. (1992). The pharmacokinetics of oral itraconazole in AIDS patients. Journal of Pharmacy and Pharmacology 44, 618-19.
28. Arévalo, M. P., Arias, A., Andreu, A., Rodriguez, C. & Sierra, A. (1994). Fluconazole, itraconazole and ketoconazole in vitro activity against Candida sp. Journal of Chemotherapy 6, 226-9.
29. Van't Wout, J. W. (1996). Fluconazole treatment of candidal infections caused by non-albicans Candida species. European Journal of Clinical Microbiology and Infectious Diseases 15, 238-42.
30. Anaissie, E., Bodey, G. P., Kantarjian, H., David, C., Barnett, K. & Bow, E. et al. (1991). Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. American Journal of Medicine 91, 142-50.
31. Finlay, P. M., Richardson, M. D. & Robertson, A. G. (1996). A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. British Journal of Oral and Maxillofacial Surgery 34, 23-5.
32. Perry, C. M., Whittington, R. & McTavish, D. (1995). Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis. Drugs 49, 984-1006.
33. Kaplan, B., Rabinerson, D. & Gibor, Y. (1997). Single-dose systemic oral fluconazole for the treatment of vaginal candidiasis. International Journal of Gynaecology and Obstetrics 57, 281-6.
34. Ikemoto, H. (1989). A clinical study of fluconazole for the treatment of deep mycoses. Diagnostic Microbiology and Infectious Disease 12, 239S-45S.
35. Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E. et al. (1994). A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine 331, 1325-30.
36. Debruyne, D. (1997). Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clinical Pharmacokinetics 33, 52-77.
37. Samonis, G., Rolston, K., Karl, C., Miller, P. & Bodey, G. P. (1990). Prophylaxis of oropharyngeal candidiasis with fluconazole. Reviews of Infectious Diseases 12, Suppl. 3, S369-73.
38. Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H. et al. (1992). A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 326, 845-51.
39. Philpott-Howard, J. N., Wade, J. J., Mufti, G. J., Brammer, K. W. & Ehninger, G. (1993). Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. Journal of Antimicrobial Chemotherapy 31, 973-84.
40. Mucke, R., Kaben, U., Libera, T., Knauerhase, H., Ziegler, P. G., Hamann, D. et al. (1998). Fluconazole prophylaxis in patients with head and neck tumours undergoing radiation and radiochemotherapy. Mycoses 41, 421-3.
41. Van Burik, J. H., Leisenring, W., Myerson, D., Hackman, R. C., Shulman, H. M., Sale, G. E. et al. (1998). The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine 77, 246-54.
42. Longman, L. P., Hibbert, S. A. & Martin, M. V. (1990). Efficacy of fluconazole in prophylaxis and treatment of experimental Candida endocarditis. Reviews of Infectious Diseases 12, Suppl. 3, S294-8.
43. Nguyen, M. H., Nguyen, M. L., Lu, V. L., McMahon, D., Keys, T. F. & Amidi, M. (1996). Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clinical Infectious Diseases 22, 262-7.
44. Viscoli, C., Castagnola, E., Fioredda, F., Ciravegna, B., Barigione, G. & Terragna, A. (1991). Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrobial Agents and Chemotherapy 35, 365-7.
45. Fasano, C., O'Keefe, J. & Gibbs, D. (1994). Fluconazole treatment of children with severe fungal infections not treatable with conventional agents. European Journal of Clinical Microbiology and Infectious Disease 13, 344-7.
46. Flynn, P. M., Cunningham, C. K., Kerkering, T., San Jorge, A. R., Peters, V. B., Pitel, P. A. et al. (1995). Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. Journal of Paediatrics 127, 322-8.
47. Presterl, E. & Graninger, W. (1994). Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. Multicentre Study Group. European Journal of Clinical Microbiology and Infectious Diseases 13, 347-51.
48. Cáp, J., Mojzesova, A., Kayserova, E., Bubánska, E., Hatiar, K., Trupl, J. et al. (1993). Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in paediatric patients with cancer. Chemotherapy 39, 438-42.
49. Ninane, J. (1994). A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. European Journal of Clinical Microbiology and Infectious Diseases 13, 330-7.
50. Driessen, M., Ellis, J. B., Muwazi, F. & De Villiers, F. P. (1997). The treatment of systemic candidiasis in neonates with oral fluconazole. Annals of Tropical Paediatrics 17, 263-71.
51. Groll, A. H., Just-Nuebling, G., Kurz, M., Mueller, C., Nowak-Goettl, U., Schwabe, D. et al. (1997). Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. Journal of Antimicrobial Chemotherapy 40, 855-62.
52. Wenzl, T. G., Schefels, J., Hornchen, H. & Skopnik, H. (1998). Pharmacokinetics of oral fluconazole in premature infants. European Journal of Pediatrics 157, 661-2.
53. Rees, T. & Phillips, R. (1992). Multicenter comparison of one-day oral therapy with fluconazole or itraconazole in vaginal candidiasis. International Journal of Gynecology and Obstetrics 37, Suppl. 1, 33S-38S.
54. Rongioletti, F., Robert, E., Tripodi, S. & Persi, A. (1992). Treatment of onychomycosis with itraconazole. Journal of Dermatological Treatment 2, 145-6.
55. Blatchford, N. R. (1990). Treatment of oral candidosis with itraconazole: a review. Journal of the American Academy of Dermatology 23, 565-7.
56. Cartledge, J. D., Midgley, J., Youle, M. & Gazzard, B. G. (1994). Itraconazole cyclodextrin solution - effective treatment for HIV-related candidiasis unresponsive to other azole therapy. Journal of Antimicrobial Chemotherapy 33, 1071-3.
57. Frechette, G., De Beule, K., Weinke, W., Tchamouroff, S. E. & Stoffels, P. (1995). Effects of itraconazole in the treatment of oral candidosis in HIV patients. A double-blind, double-dummy, randomized comparison with fluconazole. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract 1219, p. 244. American Society for Microbiology, Washington, DC.
58. Graybill, J. R., Vazquez, J., Darouiche, R. O., Mohart, R., Moskovitz, B. L. & Mallegol, I. (1995). Itraconazole oral solution (IS) versus fluconazole (F) treatment of oropharyngeal candidiasis (OC). In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract 1009, p. 244. American Society for Microbiology, Washington, DC.
59. Morgenstern, G. R., Prentice, A. G., Prentice, H. G., Ropner, J. E., Schey, S. A. & Warnock, D. W. (1996). Itraconazole oral solution versus fluconazole suspension for antifungal prophylaxis in neutropenic patients. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract LM34. American Society for Microbiology, Washington, DC.
60. Wilcox, C. M., Darouiche, R. O., Laine, L., Moskovitz, B. L., Mallegol, I. & Wu, J. (1997). A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. Journal of Infectious Diseases 176, 227-32.
61. Phillips, P., De Beule, K., Frechette, G., Tchamouroff, S., Vandercam, B., Weitner, L. et al. (1998). A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clinical Infectious Diseases 26, 1368-73.
62. Johnson, E. M. & Warnock, D. W. (1995). Azole drug resistance in yeasts. Journal of Antimicrobial Chemotherapy 36, 751-5.
63. Rex, J. H., Rinaldi, M. G. & Pfaller, M. A. (1995). Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy 39, 1-8.
64. Hunter, K. D., Gibson, J., Lockhart, P., Pithie, A. & Bagg, J. (1998). Fluconazole-resistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 85, 558-64.
65. Field, E. A., Millns, B., Pearce, P. K., Martin, M. V., Parkinson, T. & Hitchcock, C. A. (1996). Fluconazole therapy of oropharyngeal candidiasis in a patient with multiple endocrine failure does not correlate with Candida albicans susceptibility to fluconazole in vitro. Journal of Medical and Veterinary Mycology 34, 205-8.
66. Marr, K. A., White, T. C., van Burik, J.-A. H. & Bowden, R. A. (1997). Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clinical Infectious Diseases 25, 908-10.
67. Milne, L. J. R. (1997). The antifungal triazoles in oropharyngeal candidosis in AIDS. Opinion in Microbiology, 9-12.
68. Ansari, A. M., Gould, I. M. & Douglas, J. G. (1990). High dose oral fluconazole for oropharyngeal candidosis in AIDS. Journal of Antimicrobial Chemotherapy 25, 720-1.
69. Redding, S. W., Pfaller, M. A., Messer, S. A., Smith, J. A., Prows, J., Bradley, L. L. et al. (1997). Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection. Journal of Clinical Microbiology 35, 1761-5.
70. National Committee for Clinical Laboratory Standards. (1992). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Proposed Standard M27-P. NCCLS, Villanova, PA.
71. Pfaller, M. A., Rex, J. H. & Rinaldi, M. G. (1997). Antifungal susceptibility testing: technical advances and potential clinical applications. Clinical Infectious Diseases 24, 776-84.
72. Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel Ingroff, A., Ghannoum, M. A. et al. (1997). Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clinical Infectious Diseases 24, 235-47.
73. Troillet, N., Durussel, C., Bille, J., Glauser, M. P. & Chave, J. P. (1993). Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. European Journal of Clinical Microbiology and Infectious Diseases 12, 911-5.
74. Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J. et al. (1994). Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility and DNA subtype analysis. Clinical Infectious Diseases 18, 240-2.
75. Ruhnke, M., Eigler, A., Engelmann, E., Geiseler, B. & Trautmann, M. (1994). Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22, 132-6.
76. Cameron, M. L., Schell, W. A., Bruch, S., Bartlett, J. A., Waskin, H. A. & Perfect, J. R. (1993). Correlation of in vitro fungal resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 37, 2449-53.
77. Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W. & Webb, C. D. (1995). Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIALD Mycoses Study Group and the Candidemia Study Group. Antimicrobial Agents and Chemotherapy 39, 40-4.
78. Ruhnke, M., Eigler, A., Tennagen, I., Geiseler, B., Engelmann, E. & Trautmann, M. (1994). Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis in human immunodeficiency virus infection. Journal of Clinical Microbiology 32, 2092-8.
79. Phillips, P., Zemcov, J., Mahmood, W., Montaner, J. S., Craib, K. & Clarke, A. M. (1996). Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 10, 1369-76.
80. Johnson, E. M., Davey, K. G., Szekely, A. & Warnock, D. W. (1995). Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. Journal of Antimicrobial Chemotherapy 36, 787-93.
81. Ruhnke, M., Schmidt-Westhausen, A. & Trautmann, M. (1997). In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 41, 575-7.
82. Inman, W., Kubota, K., Pearce, G. & Wilton, L. (1993). PEM Report Number 3 - Fluconazole. Pharmacoepidemiology and Drug Safety 2, 321-40.
83. -1. Mycoses 40, 267-77.
84. Stevens, D. A., Diaz, M., Negroni, R., Montera Gei, F., Castro, L. G., Sampaio, S. A. et al. (1997). Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group. Chemotherapy 43, 371-7.
85. Osterloh, I. H. (1992). Fluconazole. In The Antifungal Agents, Vol. 1, (Johnson, S. & Johnson, F. N., Eds), pp. 40-60. Marius Press.
86. Berry, A. J., Rinaldi, M. G. & Graybill, J. R. (1992). Use of highdose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrobial Agents and Chemotherapy 36, 690-2.
87. Haubrich, R. H., Haghighat, D., Bozzette, S. A., Tilles, J. & McCutchan, J. A. (1994). High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. Journal of Infectious Diseases 170, 238-42.
88. Wheat, L., Mawhinney, S., Hafner, R. & McKinsey, D. (1994). Fluconazole treatment for histoplasmosis in AIDS: prospective multi-center non-comparative trial. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract 1233. American Society for Microbiology, Washington, DC.
89. Jacobson, M. A., Hanks, D. K. & Ferrell, L. D. (1994). Fatal acute hepatic necrosis due to fluconazole. American Journal of Medicine 96, 188-90.
90. Bronstein, J. A., Gros, P., Hernandez, E., Larroque, P. & Molinie, C. (1997). Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clinical Infectious Diseases 25, 1266-7.
91. Uekama, K. & Otagiri, M. (1987). Cyclodextrins in drug carrier systems. Critical Reviews in Therapeutic Drug Carrier Systems 3, 1-40.
92. Gerloczy, A., Hoshino, T. & Pitha, J. (1994). Safety of oral cyclodextrins: effects of hydroxypropyl cyclodextrins, cyclodextrin sulfates and cationic cyclodextrins on steroid balance in rats. Journal of Pharmaceutical Sciences 83, 193-6.
93. Sharkey, P. K., Rinaldi, M. G., Dunn, J. F., Hardin, T. C., Fetchick, R. J. & Graybill, J. R. (1991). High-dose itraconazole in the treatment of severe mycoses. Antimicrobial Agents and Chemotherapy 35, 707-13.